Covered recipient · General Payments record
KATHERINE K MYERHOLTZ
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$1,003.15
- Reported across 61 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $178.59 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $40.73 | 2 |
| Xeris Pharmaceuticals, Inc. | $22.95 | 1 |
| Alkermes, Inc. | $22.07 | 1 |
| GlaxoSmithKline, LLC. | $21.44 | 1 |
| Acerta Pharma LLC | $21.38 | 1 |
| Merck Sharp & Dohme Corporation | $19.84 | 1 |
| Otsuka America Pharmaceutical, Inc. | $16.18 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.63 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107714407 | CMS |
| ABBVIE INC. | $23.10 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107714409 | CMS |
| Alkermes, Inc. | $22.07 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120560638 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.38 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104384221 | CMS |
| GlaxoSmithKline, LLC. | $21.44 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116097013 | CMS |
| Merck Sharp & Dohme LLC | $19.84 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141942217 | CMS |
| Otsuka America Pharmaceutical, Inc. | $16.18 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119146763 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.00 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153438348 | CMS |
| Xeris Pharmaceuticals, Inc. | $22.95 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144630721 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.